Divi’s Labs Q4 Review - Strong Performance Continues: ICICI Securities

An employee inspects a tray of Concor cardiovascular treatment tablets inside pharmaceutical laboratories. (Photographer: Martin Leissl/Bloomberg).

Divi’s Labs Q4 Review - Strong Performance Continues: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

Divi’s Laboratories Ltd. reported Q4 FY21 performance marginally higher than our estimates.

Consolidated revenue grew 28.7% YoY to Rs 17.9 billion (our estimate: Rs 17.0 billion), Ebitda margin improved 810 basis points YoY to 40.1% (our estimate: 40.5%) and profit after tax grew 29.3% to Rs 5.0 billion (our estimate: Rs 4.9 billion).

The growth was driven across generic active pharmaceutical ingredients and contract research and manufacturing service businesses.

Strong positioning of the company will help in monetising the growth opportunity in API and CRAMS space given its stellar execution track record and being one of the preferred suppliers.

Click on the attachment to read the full report:

ICICI Securities Divis Labs Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.